Clinical Trials Directory

Trials / Completed

CompletedNCT01890057

The Dose of Sugammadex for Rapid Reversal of Profound Neuromuscular Block in Young and Elderly Patients

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
44 (actual)
Sponsor
Severance Hospital · Academic / Other
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

To find out the dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes from profound rocuronium-induced neuromuscular block in young and elderly adult patients.

Detailed description

A previous study reported that elderly patients required a longer time to recover from rocuronium induced neuromuscular block compared to younger patients. Therefore, the aim of this study is to find out the dose of sugammadex for rapid recovery from profound neuromuscular block in young and elderly adult patients.

Conditions

Interventions

TypeNameDescription
DRUGSugammadexThe dose of sugammadex

Timeline

Start date
2013-06-01
Primary completion
2014-01-01
Completion
2014-01-01
First posted
2013-07-01
Last updated
2014-02-04

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT01890057. Inclusion in this directory is not an endorsement.

The Dose of Sugammadex for Rapid Reversal of Profound Neuromuscular Block in Young and Elderly Patients (NCT01890057) · Clinical Trials Directory